Equity Profile

KYMR

Kymera Therapeutics, Inc.

Health CareBiotechnology$6.4B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth indicates how well the company is expanding its business and capturing market share.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KYMR Q2-2026 Earnings Preview

Context

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as the demand for advanced medical treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-4.04%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1-2026, Kymera reported an EPS of -$0.71, which was better than analysts' expectations of -$0.89, resulting in a positive surprise of 20.4%. However, the stock saw a slight decline of 0.54% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, hoping for improved EPS and signs of revenue growth. The company's recent performance has shown mixed results, leading to uncertainty.

Bull Case

If Kymera can demonstrate significant progress in its drug development pipeline and report better-than-expected EPS, it could boost investor confidence and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations or reveals setbacks in its research efforts, it could lead to a negative reaction from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

What updates can management provide on the drug development pipeline?

Insights into the progress of ongoing research and development projects are vital for assessing the company's future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kymera's potential for a significant EPS improvement based on recent advancements in its drug pipeline.

Supporting Evidence

The options market is pricing in a 23.64% move, suggesting traders expect substantial volatility.

Kymera's history of beating EPS estimates suggests potential for positive surprises.

Key Risk

If the EPS comes in better than -$0.60, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to improve profitability and advance its drug pipeline, which are critical for future growth.

Bull Confirmed If

A positive EPS of -$0.60 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.80 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.64%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant move of approximately 23.64%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±23.6% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.0%

Calls (0)P/C Ratio: 1.00Puts (14K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$2.1M

23,692 sh

3 insiders

Net

$2.1M

Net selling

Most Active Insiders· 11 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kymera beats expectations, history suggests the stock could rise by around 2.16% on the first day after the report.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting ongoing uncertainty.

Miss

A disappointing earnings report could lead to a decline of approximately 4.14%, as seen in past quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the progress of drug candidates in the pipeline.
2Updates on partnerships or collaborations that could enhance growth.
3Insights into R&D spending and its impact on future profitability.
4Management's perspective on market conditions affecting the biotech sector.
5Any guidance on future earnings expectations or strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth indicates how well the company is expanding its business and capturing market share.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KYMR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-4.04%

Avg Stock Reaction

-3.15%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Kymera can demonstrate significant progress in its drug development pipeline and report better-than-expected EPS, it could boost investor confidence and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations or reveals setbacks in its research efforts, it could lead to a negative reaction from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.

What updates can management provide on the drug development pipeline?

Insights into the progress of ongoing research and development projects are vital for assessing the company's future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kymera's potential for a significant EPS improvement based on recent advancements in its drug pipeline.

Supporting Evidence

The options market is pricing in a 23.64% move, suggesting traders expect substantial volatility.

Kymera's history of beating EPS estimates suggests potential for positive surprises.

Key Risk

If the EPS comes in better than -$0.60, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to improve profitability and advance its drug pipeline, which are critical for future growth.

Bull Confirmed If

A positive EPS of -$0.60 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.80 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.64%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant move of approximately 23.64%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±23.6% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.0%

Calls (0)P/C Ratio: 1.00Puts (14K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$2.1M

23,692 sh

3 insiders

Net

$2.1M

Net selling

Most Active Insiders· 11 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kymera beats expectations, history suggests the stock could rise by around 2.16% on the first day after the report.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting ongoing uncertainty.

Miss

A disappointing earnings report could lead to a decline of approximately 4.14%, as seen in past quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the progress of drug candidates in the pipeline.
2Updates on partnerships or collaborations that could enhance growth.
3Insights into R&D spending and its impact on future profitability.
4Management's perspective on market conditions affecting the biotech sector.
5Any guidance on future earnings expectations or strategic initiatives.